Rhenman & Partners Asset Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Rhenman & Partners Asset Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.49M	Buy	384,800 +145,300	+61%	+$2.63M	0.71%	59
2026 Q1	$4.46M	Sell	239,500 -124,500	-34%	-$2.06M	0.55%	60
2025 Q4	$4.8M	Buy	364,000 +157,000	+76%	+$1.85M	0.45%	65
2025 Q3	$1.48M	Buy	207,000 +162,000	+360%	+$8.44M	0.16%	86
2025 Q2	$2.12M	Hold	45,000	–	–	0.27%	70
2025 Q1	$1.76M	Buy	+45,000	New	+$1.94M	0.2%	72

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Rhenman & Partners Asset Management's MLTX Position: Q2 2026 in Review

Rhenman & Partners Asset Management increased its MoonLake Immunotherapeutics (MLTX) stake by 61% in Q2 2026, buying an estimated $2.63M and bringing the position to 384,800 shares worth $7.49M. The position accounts for 0.71% of the portfolio, ranked #59.

Rhenman & Partners Asset Management first reported a position in MLTX in Q1 2025 and has held it in 6 quarters since. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Rhenman & Partners Asset Management held 384,800 shares of MoonLake Immunotherapeutics worth $7.49M as of Q2 2026.
Rhenman & Partners Asset Management bought 145,300 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $2.63M.
MoonLake Immunotherapeutics made up 0.71% of Rhenman & Partners Asset Management's portfolio in Q2 2026, its #59 holding.
Rhenman & Partners Asset Management first reported a position in MoonLake Immunotherapeutics in Q1 2025 and has held it in 6 quarters since.
173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.